Hepatitis C Diagnostic Summit 2016
ShareCompartir
Welcome - Jonathan Mermin, MD, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC
Opening remarks & Setting the Stage for the Summit - John Ward, MD, Division of Viral Hepatitis, CDC
Session I: Diagnosis and Management of Current HCV Infection – From HCV Testing to Cure
Moderators: Michael Fried, MD and Daniel Johnson, MD
| Testing for diagnosis of current HCV infection Lesley Miller, MD, Emory University School of Medicine/Grady Hospital |
| Testing for management and monitoring of anti-viral therapy Adrian Di Bisceglie, MD, Saint Louis University School of Medicine, St Louis, MO |
| Testing for relapse versus re-infection and on-going exposures Brian Edlin, MD, Medical officer, NCHHSTP, CDC |
| Testing of high-risk and special populations W. Ray Kim, MD, Stanford University Medical Center, Stanford, CA |
| HCV national surveillance Scott Holmberg, MD, Division of Viral Hepatitis, CDC |
| Roundtable of speakers with Q&As |
Session II: HCV Diagnostics: the Clinical and Public Health Laboratory Setting - Policy, Practice and Data
Moderators: Bernie Branson, MD and Jeffrey Engel, MD
| Testing practices and platforms, and challenges in implementing CDC’s updated hepatitis C testing guidelines LabCorp - Christos Petropoulos, PhD Quest Diagnostics - Rick Pesano, MD, PhD Cleveland Clinic - Belinda Yen-Lieberman, PhD |
| Use of commercial lab data for public health action Susan Hariri, PhD, Division of Viral Hepatitis, CDC |
| Roundtable of speakers with Q&As |
Session III: Expanding Access to Quality HCV Diagnostics Globally Especially in Resource-limited Settings
Moderators: Claudia Denkinger, MD and John Ward, MD
| Overview of global gaps in diagnostics Francisco Averhoff, MD, Division of Viral Hepatitis, CDC |
| Efforts to improve and make HCV Diagnostics affordable globally Claudia Denkinger, MD, Tuberculosis and Hepatitis Program, FIND |
| The pursuit of ‘good enough’ in hepatitis C diagnostics Camila Graham, MD, Beth Israel Deaconess Medical Center, Boston, MA |
| MSF experience with HCV screening, care and monitoring Anne Loarec, MD, Médecins Sans Frontières / Doctors without Borders |
| Development of WHO standards for HCV NATs Julia Kreß, PhD, Paul Ehrlich Institute |
| CDC’s efforts in improving diagnostics: development of proficiency panels Saleem Kamili, PhD, Division of Viral Hepatitis, CDC |
| Roundtable of speakers with Q&As |
| Closing remarks John Ward, MD, Division of Viral Hepatitis, CDC |
Opening remarks - John Ward, MD, Division of Viral Hepatitis, CDC
Session IV: HCV Diagnostics – New and Improved Technologies
Moderators: Saleem Kamili, PhD and Steve Lovell, PhD
| Current diagnostic landscape in HCV Bernie Branson, MD, Scientific Affairs |
| HCV core antigen Assay George Dawson, PhD, Abbott |
| Point-of-care HCV antibody assays Michael Reed, PhD, Orasure |
| Point-of-care HCV core antigen test development Hong Qi, PhD, Qoo labs |
| Point-of-care HCV RNA test Tanya Applegate, PhD, Kirby Institute, UNSW, AU |
| Integrated testing for multiple pathogens - Virome analysis Christiane Honisch, PhD, Illumina |
| Roundtable of speakers with Q&As |
Session V: U.S. Public Health role in HCV Detection, Investigation and Response
Moderator: Carolyn Wester, MD, MPH
| Public Health Lab Capacity in the United States Anne Gaynor, PhD, Association of Public Health Laboratories |
| Challenges in using Laboratory Developed Tests in HCV Diagnostics Monica Parker, PhD, New York State Department of Health |
| Regulatory issues in diagnostic development Steve Lovell, PhD, FDA |
| Cost-effectiveness of various HCV testing strategies Michael Chapko, PhD, University of Washington |
| Roundtable of speakers with Q/A |
Session V: U.S. Public Health role in HCV Detection, Investigation and Response
Moderator: Greg Armstrong, MD
| Evolving a state laboratory diagnostic capacity during an HCV outbreak Fengxiang Gao, PhD, New Hampshire State Department of Health |
| Next Generation Sequencing Technology Lilia Ganova-Raeva, PhD, Division of Viral Hepatitis, CDC |
| GHOST – outbreak investigations and molecular surveillance Yury Khudyakov, PhD, Division of Viral Hepatitis, CDC |
| Implementation of GHOST – a Pilot site Linda Thomas, MS, Tennessee State Department of Health |
| Roundtable of speakers with Q/A |
| Panel Discussion: Key programmatic and policy issues impacting health departments in regards to hepatitis C Carolyn Wester, MD, MPH; Doug Thoroughman, PhD, MS; Liisa M. Randall, PhD |
| Wrap-up and closing remarks John Ward, MD, Division of Viral Hepatitis, CDC |
Hepatitis C Diagnostic Summit Brochure [PDF - 4 pages]
Speakers and Moderators
Francisco Averhoff, MD
Adrian Di Bisceglie, MD
Bernie Branson, MD
Michael Chapko, PhD
George Dawson, PhD
Claudia Denkinger, MD
Brian Edlin, MD
Jeffrey Engel, MD
Michael Fried, MD
Anne Gaynor, PhD
Lilia Ganova-Raeva, PhD
Fengxiang Gao, PhD
Camila Graham, MD
Susan Hariri, PhD
Scott Holmberg, MD
Christiane Honisch, PhD
Daniel Johnson, MD
Saleem Kamili, PhD
Yury Khudyakov, PhD
W. Ray Kim, MD
Maja Kodani, PhD
Julia Kreß, PhD
Anne Loarec, MD
Steve Lovell, PhD
Lesley Miller, MD
Monica Parker, PhD
Rick Pesano, MD, PhD
Christos Petropoulos, PhD
Hong Qi, PhD
Liisa M. Randall, PhD.
Michael Reed, MD
Linda Thomas, MS
Doug Thoroughman, PhD, MS
John W. Ward, MD
Carolyn Wester, MD, MPH
Belinda Yen-Lieberman, PhD
Organizing Committee
Saleem Kamili, PhD
Division of Viral Hepatitis, CDC
John W. Ward, MD
Division of Viral Hepatitis, CDC
Anne M. Gaynor, PhD
Association of Public Health Laboratories
Claudia Denkinger, MD
Foundation for Innovative New Diagnostics
- Page last reviewed: April 3, 2017
- Page last updated: April 3, 2017
- Content source: